The announcement of Regeneron's forecasted R&D and SG&A expenses for 2024 suggests a strategic investment in future growth and operational efficiency. This could be viewed positively by investors as it indicates the company's commitment to innovation and market competitiveness. The substantial investment in R&D is particularly indicative of a focus on developing new products and enhancing its pipeline, which could lead to future revenue growth. However, the impact on the stock price would also depend on the broader market perception of these investments and the company's ability to manage costs effectively.